AU2010306755B2 - Pharmaceutical formulations of nitrite and uses thereof - Google Patents

Pharmaceutical formulations of nitrite and uses thereof Download PDF

Info

Publication number
AU2010306755B2
AU2010306755B2 AU2010306755A AU2010306755A AU2010306755B2 AU 2010306755 B2 AU2010306755 B2 AU 2010306755B2 AU 2010306755 A AU2010306755 A AU 2010306755A AU 2010306755 A AU2010306755 A AU 2010306755A AU 2010306755 B2 AU2010306755 B2 AU 2010306755B2
Authority
AU
Australia
Prior art keywords
nitrite
pharmaceutical composition
human
pharmaceutically acceptable
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010306755A
Other languages
English (en)
Other versions
AU2010306755A1 (en
Inventor
Panayiotis P. Constantinides
Douglas R. Flanagan
Anthony Giordano
Christopher Kevil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TheraVasc Inc
Original Assignee
TheraVasc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TheraVasc Inc filed Critical TheraVasc Inc
Publication of AU2010306755A1 publication Critical patent/AU2010306755A1/en
Application granted granted Critical
Publication of AU2010306755B2 publication Critical patent/AU2010306755B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010306755A 2009-10-14 2010-10-14 Pharmaceutical formulations of nitrite and uses thereof Ceased AU2010306755B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25148309P 2009-10-14 2009-10-14
US61/251,483 2009-10-14
PCT/US2010/052683 WO2011047161A1 (en) 2009-10-14 2010-10-14 Pharmaceutical formulations of nitrite and uses thereof

Publications (2)

Publication Number Publication Date
AU2010306755A1 AU2010306755A1 (en) 2012-05-03
AU2010306755B2 true AU2010306755B2 (en) 2015-12-24

Family

ID=43855036

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010306755A Ceased AU2010306755B2 (en) 2009-10-14 2010-10-14 Pharmaceutical formulations of nitrite and uses thereof

Country Status (10)

Country Link
US (4) US10463689B2 (enExample)
EP (1) EP2488035B1 (enExample)
JP (3) JP5758904B2 (enExample)
CN (2) CN102686111A (enExample)
AU (1) AU2010306755B2 (enExample)
CA (1) CA2777066C (enExample)
ES (1) ES2633618T3 (enExample)
IL (1) IL219155A0 (enExample)
IN (1) IN2012DN03428A (enExample)
WO (1) WO2011047161A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101939014B (zh) 2007-11-15 2016-04-27 路易斯安那州大学及农业和机械学院管理委员会 亚硝酸盐在慢性缺血中的应用
US9241999B2 (en) 2009-06-15 2016-01-26 Board Of Regents Of The University Of Texas System Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
US20120237617A1 (en) 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
IN2012DN03428A (enExample) 2009-10-14 2015-10-23 Theravasc Inc
US8627204B2 (en) * 2011-10-18 2014-01-07 Microsoft Corporation Custom optimization of web pages
ES2741146T3 (es) * 2013-02-20 2020-02-10 The Board Of Supervisors Of The Louisiana State Univ Mechanical And Agricultural College Formulaciones farmacéuticas de nitrio y sus usos
CN105339006A (zh) * 2013-05-10 2016-02-17 尼特罗米加公司 含有脂肪酸和亚硝酸盐的营养或膳食补充剂
GB201309092D0 (en) 2013-05-20 2013-07-03 Edixomed Ltd Transdermal delivery system
US20170349438A1 (en) 2016-06-06 2017-12-07 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
US11116731B2 (en) 2017-02-20 2021-09-14 Brd. of Sup. of LSU and A &M College Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation
US11850271B1 (en) * 2023-05-16 2023-12-26 King Faisal University Topical skin cream
WO2026006722A1 (en) 2024-06-28 2026-01-02 The Regents Of The University Of Michigan Nitric oxide generating medical devices and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994444A (en) * 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US20070154569A1 (en) * 2003-07-09 2007-07-05 The Govt. of the U.S.A. through The Dept. of Health and Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US20090196930A1 (en) * 2007-12-27 2009-08-06 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914446A (en) * 1958-06-26 1959-11-24 Upjohn Co Nitrite stabilized ascorbic acid-cyanocobalamin compositions
US4650484A (en) 1983-02-03 1987-03-17 Alza Corporation Method for treating ischemic conditions
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US5122384A (en) 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US6709681B2 (en) 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US5770645A (en) 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US7015876B1 (en) * 1998-06-03 2006-03-21 Lear Corporation Heads-up display with improved contrast
EP1105146A1 (en) 1998-07-14 2001-06-13 Paracelsian, Inc. Method for identifying and confirming consistent bio-functionality of natural compositions
EP1146862B1 (de) 1999-01-29 2003-04-23 Disphar International B.V. Pharmazeutische zusammensetzungen
GB9905425D0 (en) 1999-03-09 1999-05-05 Queen Mary & Westfield College Pharmaceutical composition
US6314956B1 (en) 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
GB0119011D0 (en) 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
US20030125714A1 (en) 2001-12-18 2003-07-03 Edgren David Emil Dosage form for time-varying patterns of drug delivery
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
US20030219494A1 (en) * 2002-03-20 2003-11-27 Smith Maree Therese Compositions and methods of using them
CA2379211A1 (fr) 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
WO2005018561A2 (en) 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2005023189A2 (en) 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
US7362274B1 (en) 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060083824A1 (en) 2004-10-20 2006-04-20 Pbm Products Llc Nutritional supplements for glucose intolerant individuals
KR20070105331A (ko) 2005-02-11 2007-10-30 노랩스 에이비 일산화질소를 포함하는 신경병증의 치료 장치, 방법 및용도
EP1883416A4 (en) 2005-05-24 2013-06-12 Wellgen Inc COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS RELATED TO INFLAMMATION
MX2008010127A (es) * 2006-02-10 2009-03-05 Mannatech Inc Formulaciones de suplementos dieteticos multivitaminicos y multiminerales naturales, para su absorcion mejorada y uso biologico.
GB0607402D0 (en) 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
WO2007149520A2 (en) 2006-06-21 2007-12-27 Albert Einstein College Of Medicine Of Yeshiva University Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof
EP3159000B1 (en) 2007-02-26 2025-05-21 HeartBeet Ltd. Performance enhancing composition
KR20100014853A (ko) 2007-02-26 2010-02-11 존 런드버그 아질산염 및 질산염의 신규 용도 및 이를 함유하는 조성물
WO2008153762A2 (en) 2007-05-25 2008-12-18 N30 Pharmaceuticals, Llc S-nitrosothiol formulations and storage systems
EP2184986A4 (en) * 2007-08-06 2010-12-15 Trinity Lab Inc PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC PAIN AND PAIN RELATING TO NEUROPATHY
CN101939014B (zh) 2007-11-15 2016-04-27 路易斯安那州大学及农业和机械学院管理委员会 亚硝酸盐在慢性缺血中的应用
WO2010036236A1 (en) 2008-09-23 2010-04-01 Baker Hughes Incorporated Anchor assembly
US8568793B2 (en) * 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
US20120237617A1 (en) 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
IN2012DN03428A (enExample) * 2009-10-14 2015-10-23 Theravasc Inc
US20130209584A1 (en) 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
US20140127329A1 (en) 2011-03-31 2014-05-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
US20140112983A1 (en) 2011-04-14 2014-04-24 Theravasc Inc. Nitrite compositions and uses thereof
US9294956B2 (en) 2011-12-29 2016-03-22 Qualcomm Incorporated Application-server-assisted preemptive multicast bearer establishment for real-time low-latency applications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994444A (en) * 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US20070154569A1 (en) * 2003-07-09 2007-07-05 The Govt. of the U.S.A. through The Dept. of Health and Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US20090196930A1 (en) * 2007-12-27 2009-08-06 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof

Also Published As

Publication number Publication date
US20200085861A1 (en) 2020-03-19
CN102686111A (zh) 2012-09-19
JP2015180674A (ja) 2015-10-15
IN2012DN03428A (enExample) 2015-10-23
AU2010306755A1 (en) 2012-05-03
JP6125567B2 (ja) 2017-05-10
CN107260756A (zh) 2017-10-20
IL219155A0 (en) 2012-06-28
CA2777066A1 (en) 2011-04-21
EP2488035B1 (en) 2017-04-26
CA2777066C (en) 2020-02-18
JP5758904B2 (ja) 2015-08-05
WO2011047161A1 (en) 2011-04-21
JP2017141275A (ja) 2017-08-17
EP2488035A1 (en) 2012-08-22
US20160067279A1 (en) 2016-03-10
US10307441B2 (en) 2019-06-04
ES2633618T3 (es) 2017-09-22
EP2488035A4 (en) 2013-07-31
US10463689B2 (en) 2019-11-05
US20200297756A1 (en) 2020-09-24
JP2013508289A (ja) 2013-03-07
US20110086069A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
US20200297756A1 (en) Pharmaceutical formulations of nitrite and uses thereof
AU2019268052B2 (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
EP2255797A2 (en) Composite preparation
BR112020024107A2 (pt) combinação farmacêutica, composição, e preparação de combinação que compreende ativador de glucoquinase e inibidor de sglt-2 e métodos de preparação e uso dos mesmos
HUP0202513A2 (en) Betha-carboline pharmaceutical compositions
JPWO2006093353A1 (ja) 放出制御組成物
CN103006612B (zh) 一种赖诺普利迟释缓释片剂及其制备方法
JPWO2006080481A1 (ja) マルチプルユニット型経口徐放性製剤及びその製造方法
CN104997748B (zh) 一种治疗高血压急症的硝苯地平缓释片剂及其制备工艺
US20150110899A1 (en) Pharmaceutical formulations of nitrite and uses thereof
KR20150003726A (ko) 프라수그렐을 함유하는 안정한 즉시방출형 경구 약제학적 조성물
EP4371558A1 (en) Sacubitril valsartan sodium sustained-release composition, and preparation method therefor and use thereof
HK1173617B (en) Pharmaceutical formulations of nitrite and uses thereof
HK1173617A (en) Pharmaceutical formulations of nitrite and uses thereof
JP4837895B2 (ja) 放出制御組成物
CN100391459C (zh) 甲磺酸多沙唑嗪缓释制剂
HK40009517A (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired